Linezolid for drug-resistant pulmonary tuberculosis

Linezolid was recently re-classified as a Group A drug by the World Health Organization (WHO) for treatment of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), suggesting that it should be included in the regimen for all patients unless contraindicated...

Celý popis

Podrobná bibliografia

Vydané v:	Cochrane database of systematic reviews Ročník 3; s. CD012836
Hlavní autori:	Singh, Bhagteshwar, Cocker, Derek, Ryan, Hannah, Sloan, Derek J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 20.03.2019
Predmet:	Antibiotics, Antitubercular - adverse effects Antibiotics, Antitubercular - therapeutic use Humans Linezolid - adverse effects Linezolid - therapeutic use Non-Randomized Controlled Trials as Topic Randomized Controlled Trials as Topic Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - mortality Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - mortality Withholding Treatment - statistics & numerical data
ISSN:	1469-493X, 1469-493X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!